市場調查報告書

非囊狀纖維化症性支氣管擴張症(NCFB)的市場洞察,流行病學,預測 2028年

Non-cystic Fibrosis Bronchiectasis (NCFB) - Market Insights, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 918177
出版日期 內容資訊 英文 152 Pages
商品交期: 最快1-2個工作天內
價格
非囊狀纖維化症性支氣管擴張症(NCFB)的市場洞察,流行病學,預測 2028年 Non-cystic Fibrosis Bronchiectasis (NCFB) - Market Insights, Epidemiology and Market Forecast - 2030
出版日期: 2020年05月01日內容資訊: 英文 152 Pages
簡介

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的非囊狀纖維化症性支氣管擴張症(NCFB)市場相關調查,疾病概要和現行的治療方法,已上市治療藥及新藥的簡介,主要7個國家的市場趨勢,流行病學的預測,市場規模,患病數的變化與預測,未滿足需求,市場成長要素及障礙等資訊總括性彙整。

目錄

第1章 重要洞察

第2章 非囊狀纖維化症性支氣管擴張症(NCFB)市場概要

  • 非囊狀纖維化症性支氣管擴張症(NCFB)的分佈(實在數值)
  • 非囊狀纖維化症性支氣管擴張症(NCFB)的分佈(預測值)

第3章 疾病背景和概要:非囊狀纖維化症性支氣管擴張症(NCFB)

  • 簡介
  • 症狀
  • 病因
  • 風險要素
  • 診斷
  • 治療

第4章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的非囊狀纖維化症性支氣管擴張症(NCFB)的總患病數
  • 主要7個國家的非囊狀纖維化症性支氣管擴張症(NCFB)的總患病數:各國

第5章 各國流行病學預測

  • 美國
    • 假設和理論的根據
    • 非囊狀纖維化症性支氣管擴張症(NCFB)的患病數
    • 非囊狀纖維化症性支氣管擴張症(NCFB)的患病數:各病型
    • 非囊狀纖維化症性支氣管擴張症(NCFB)的患病數:性別
    • 非囊狀纖維化症性支氣管擴張症(NCFB)的診斷數
    • 非囊狀纖維化症性支氣管擴張症(NCFB)的治療有效的病例數
  • 歐盟5國
    • 德國
      • 假設和理論的根據
      • 非囊狀纖維化症性支氣管擴張症(NCFB)的患病數
      • 非囊狀纖維化症性支氣管擴張症(NCFB)的患病數:各病型
      • 非囊狀纖維化症性支氣管擴張症(NCFB)的患病數:性別
      • 非囊狀纖維化症性支氣管擴張症(NCFB)的診斷數
      • 非囊狀纖維化症性支氣管擴張症(NCFB)的治療有效的病例數
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本
    • 假設和理論的根據
    • 非囊狀纖維化症性支氣管擴張症(NCFB)的患病數
    • 非囊狀纖維化症性支氣管擴張症(NCFB)的患病數:各病型
    • 非囊狀纖維化症性支氣管擴張症(NCFB)的患病數:性別
    • 非囊狀纖維化症性支氣管擴張症(NCFB)的診斷數
    • 非囊狀纖維化症性支氣管擴張症(NCFB)的治療有效的病例數

第6章 現行治療

  • 治療流程
  • 治療指南

第7章 未滿足需求

第8章 案例研究

第9章 已上市治療藥

  • 醫藥品 A
    • 產品概要
    • 產品開發趨勢
    • 臨床趨勢
    • 安全性和有效性
    • 產品簡介
  • 醫藥品 B

第9章 開發平台治療藥概要

第10章 Key Cross Competition

第11章 新藥

  • 醫藥品 C
    • 產品概要
    • 臨床實驗趨勢
    • 安全性和有效性
    • 優點和缺點
    • 開發平台開發趨勢
    • 產品簡介
  • 醫藥品 D

第12章 主要7個國家的非囊狀纖維化症性支氣管擴張症(NCFB)市場分析

  • 主要7個國家的非囊狀纖維化症性支氣管擴張症(NCFB)的市場規模
  • 主要7個國家的非囊狀纖維化症性支氣管擴張症(NCFB)的市場佔有率
  • 主要7個國家的非囊狀纖維化症性支氣管擴張症(NCFB)的銷售量:各產品

第13章 非囊狀纖維化症性支氣管擴張症(NCFB)市場分析:各國

  • 美國
    • 市場規模
    • 市場佔有率:各已上市治療藥物
    • 銷售量:各產品
    • 新藥與其影響分析
  • 歐盟5國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第14章 市場成長要素

第15章 市場障礙

第16章 附錄

第17章 調查手法

第18章 DelveInsight的服務內容

第19章 免責聲明

第20章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0689

DelveInsight's 'Non-cystic Fibrosis Bronchiectasis (NCFB) - Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of NCFB in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Non-cystic Fibrosis Bronchiectasis (NCFB) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2030

Non-cystic Fibrosis Bronchiectasis (NCFB) - Disease Understanding and Treatment Algorithm

Bronchiectasis is a chronic inflammatory lung disease. It is characterized by permanent dilatation of the bronchial tree which leads to chronic sputum production and impaired bacterial clearance. The affected parts of the lungs develop a vicious cycle of failed pathogen clearance leading to frequent infections, chronic inflammation, and ongoing structural damage. The main symptoms are daily cough, daily sputum production, and frequent respiratory infections. In patients without cystic fibrosis, the condition is known as non-cystic fibrosis bronchiectasis (NCFB). Although NCFB was once a very uncommon diagnosis, in the last two decades, its prevalence has been increasing, making it more likely that primary care clinicians will encounter these patients in their practice.

The treatment of bronchiectasis focuses on managing symptoms, slowing the decline in lung function, and preventing exacerbations. Patients should be encouraged to take general changes that will make a large difference, such as smoking cessation. Chest physiotherapy is a well-established treatment with little in the way of side effects. Some patients may respond to more specialist treatments, such as regular antibiotics, often in the form of a low-dose macrolide three times a week. Frailty and co-morbidities play a role in deciding on the appropriateness of these treatments.

The DelveInsight Non-cystic Fibrosis Bronchiectasis (NCFB) market report gives the thorough understanding of the Non-cystic Fibrosis Bronchiectasis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, complications, biomarkers and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Non-cystic Fibrosis Bronchiectasis in the US, Europe and Japan.

Non-cystic Fibrosis Bronchiectasis Epidemiology

The Non-cystic Fibrosis Bronchiectasis (NCFB) epidemiology division provides the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalence, Diagnosed Population, Etiology associated with NCFB, Gender-specific Prevalent Population, Severity and Microbiology of NCFB) scenario of Non-cystic Fibrosis Bronchiectasis (NCFB) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.

According to DelveInsight, the total number of prevalent cases of Non-cystic Fibrosis Bronchiectasis (NCFB) in 7 MM was found to be 772,285 in the year 2017.

Non-cystic Fibrosis Bronchiectasis Drug Chapters

This segment of the Non-cystic Fibrosis Bronchiectasis report encloses the detailed analysis of marketed drugs and early stage (Phase-I and Phase-II) pipeline drugs along with other promising candidates. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

A multidisciplinary treatment approach is usually followed internationally for the management of NCFB and the market consequently can be divided into segments based on revenue generated by therapies which include pain control, management of exocrine and endocrine insufficiency and management of other complications. However, there are important points to be noted such as the fact that there are not curative treatment options at present and all the therapies used are either off-label or symptomatic in nature.

Non-cystic Fibrosis Bronchiectasis Market Outlook

The Non-cystic Fibrosis Bronchiectasis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Non-cystic Fibrosis Bronchiectasis in 7MM was found to be USD 1,211 Million in 2017, and is expected to increase during the course of the study period (2017-2030). Among the 7MM, the United States accounts for the largest market size of NCFB, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Non-cystic Fibrosis Bronchiectasis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Non-cystic Fibrosis Bronchiectasis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Non-cystic Fibrosis Bronchiectasis Report Key Strengths

  • 11 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Non-cystic Fibrosis Bronchiectasis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits:

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Non-cystic Fibrosis Bronchiectasis market
  • Organize sales and marketing efforts by identifying the best opportunities for Non-cystic Fibrosis Bronchiectasis market
  • To understand the future market competition in the Non-cystic Fibrosis Bronchiectasis market.

Table of Contents

1. Key Insights

2. Non-Cystic Fibrosis Bronchiectasis Market Overview at a Glance

    • 2.1.1. Market Share (%) Distribution of NCFB in 2017
    • 2.1.2. Market Share (%) Distribution of NCFB in 2030

3. Disease Background and Overview

    • 3.1.1. Introduction
    • 3.1.2. Etiology and manifestations
    • 3.1.3. Symptoms
    • 3.1.4. Pathophysiology
    • 3.1.5. Diagnosis
    • 3.1.6. Prognosis

4. Treatment and management

5. Epidemiology and Patient Population

    • 5.1.1. Key Findings
    • 5.1.2. Total Prevalence of Non-cystic Fibrosis Bronchiectasis in 7MM

6. Country Wise-Epidemiology

  • 6.1. United States
    • 6.1.1. Assumptions and Rationale
    • 6.1.2. Prevalence of Non-cystic fibrosis bronchiectasis
    • 6.1.3. Diagnose prevalence of NCFB in United States
    • 6.1.4. Gender Specific Diagnosed prevalence NCFB in United States
    • 6.1.5. Severity Specific Diagnosed prevalence NCFB in United States
    • 6.1.6. Etiology associated with NCFB in United States
    • 6.1.7. Microbiology of NCFB patients in United States
  • 6.2. EU-5
    • 6.2.1. Assumptions and Rationale
    • 6.2.2. Germany
      • 6.2.2.1. Prevalence of Non-cystic fibrosis bronchiectasis
      • 6.2.2.2. Diagnose prevalence of NCFB in Germany
      • 6.2.2.3. Gender Specific Diagnosed prevalence NCFB in Germany
      • 6.2.2.4. Severity Specific Diagnosed prevalence NCFB in Germany
      • 6.2.2.5. Etiology associated with NCFB in Germany
      • 6.2.2.6. Microbiology of NCFB patients in Germany
    • 6.2.3. France
      • 6.2.3.1. Prevalence of Non-cystic fibrosis bronchiectasis in France
      • 6.2.3.2. Diagnose prevalence of NCFB in France
      • 6.2.3.3. Gender Specific Diagnosed prevalence NCFB in France
      • 6.2.3.4. Severity Specific Diagnosed prevalence NCFB in France
      • 6.2.3.5. Etiology associated with NCFB in France
      • 6.2.3.6. Microbiology of NCFB patients in France
    • 6.2.4. Italy
      • 6.2.4.1. Prevalence of Non-cystic fibrosis bronchiectasis in Italy
      • 6.2.4.2. Diagnose prevalence of NCFB in Italy
      • 6.2.4.3. Gender Specific Diagnosed prevalence NCFB in Italy
      • 6.2.4.4. Severity Specific Diagnosed prevalence NCFB in Italy
      • 6.2.4.5. Etiology associated with NCFB in Italy
      • 6.2.4.6. Microbiology of NCFB patients in Italy
    • 6.2.5. Spain
      • 6.2.5.1. Prevalence of Non-cystic fibrosis bronchiectasis in Spain
      • 6.2.5.2. Diagnose prevalence of NCFB in Spain
      • 6.2.5.3. Gender Specific Diagnosed prevalence NCFB in Spain
      • 6.2.5.4. Severity Specific Diagnosed prevalence NCFB in Spain
      • 6.2.5.5. Etiology associated with NCFB in Spain
      • 6.2.5.6. Microbiology of NCFB patients in Spain
    • 6.2.6. United Kingdom
      • 6.2.6.1. Prevalence of Non-cystic fibrosis bronchiectasis in the UK
      • 6.2.6.2. Diagnose prevalence of NCFB in the UK
      • 6.2.6.3. Gender Specific Diagnosed prevalence NCFB in UK
      • 6.2.6.4. Severity Specific Diagnosed prevalence NCFB in UK
      • 6.2.6.5. Etiology associated with NCFB in UK
      • 6.2.6.6. Microbiology of NCFB patients in UK
    • 6.2.7. Japan
      • 6.2.7.1. Assumptions and Rationale
      • 6.2.7.2. Prevalence of Non-cystic fibrosis bronchiectasis in Japan
      • 6.2.7.3. Diagnose prevalence of NCFB in Japan
      • 6.2.7.4. Gender Specific Diagnosed prevalence NCFB in Japan
      • 6.2.7.5. Severity Specific Diagnosed prevalence NCFB in Japan
      • 6.2.7.6. Etiology associated with NCFB in Japan
      • 6.2.7.7. Microbiology of NCFB patients in Japan

7. Unmet needs

8. Emerging Drugs

  • 8.1. Ciprofloxacin dispersion for inhalation: Aradigm Corporation
    • 8.1.1. Product Description
    • 8.1.2. Product Development Activities
    • 8.1.3. Clinical development
    • 8.1.4. Clinical Trials Information
    • 8.1.5. Safety and Efficacy
    • 8.1.6. Product Profile
  • 8.2. Colistimethate sodium: Zambon
    • 8.2.1. Product Description
    • 8.2.2. Product Development Activities
    • 8.2.3. Clinical development
    • 8.2.4. Clinical Trials Information
    • 8.2.5. Product Profile
  • 8.3. Tobramycin inhalation powder (TIP): Novartis Pharmaceuticals
    • 8.3.1. Product Description
    • 8.3.2. Product Development Activities
    • 8.3.3. Clinical development
    • 8.3.4. Clinical Trials Information
    • 8.3.5. Product Profile
  • 8.4. INS1007: Insmed Incorporated
    • 8.4.1. Product Description
    • 8.4.2. Other Development Activities
    • 8.4.3. Clinical Development
    • 8.4.4. Clinical Trials Information
    • 8.4.5. Safety and Efficacy
    • 8.4.6. Product Profile

9. Market Outlook by Country

  • 9.1. Key Findings
  • 9.2. Market size of Non-cystic Fibrosis Bronchiectasis in 7MM
  • 9.3. The United States: Market Outlook
  • 9.4. United States Market Size
    • 9.4.1. Total Market Size of Non-cystic Fibrosis Bronchiectasis
    • 9.4.2. Non-cystic Fibrosis Bronchiectasis Market Size by Therapy
  • 9.5. EU-5 Countries: Market Outlook
    • 9.5.1. Germany Market Size
      • 9.5.1.1. Total Market Size of Non-cystic Fibrosis Bronchiectasis
      • 9.5.1.2. Non-cystic Fibrosis Bronchiectasis Market Size by Therapy
    • 9.5.2. France Market Size
      • 9.5.2.1. Total Market Size of Non-cystic Fibrosis Bronchiectasis
      • 9.5.2.2. Non-cystic Fibrosis Bronchiectasis Market Size by Therapy
    • 9.5.3. Spain Market Size
      • 9.5.3.1. Total Market Size of Non-cystic Fibrosis Bronchiectasis
      • 9.5.3.2. Non-cystic Fibrosis Bronchiectasis Market Size by Therapy
  • 9.6. Italy Market Size
    • 9.6.1. Total Market Size of Non-cystic Fibrosis Bronchiectasis
    • 9.6.2. Non-cystic Fibrosis Bronchiectasis Market Size by Therapy
  • 9.7. United Kingdom Market Size
    • 9.7.1. Total Market Size of Non-cystic Fibrosis Bronchiectasis
    • 9.7.2. Non-cystic Fibrosis Bronchiectasis Market Size by Therapy
  • 9.8. Japan: Market Outlook
    • 9.8.1. Total Market Size of Non-cystic Fibrosis Bronchiectasis
    • 9.8.2. Non-cystic Fibrosis Bronchiectasis Market Size by Therapy

10. Market Drivers

11. Market Barriers

12. Appendix

  • 12.1. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight

List of Tables

  • Table 1 Conditions associated with the development of bronchiectasis
  • Table 2 Total Prevalent Population of NCFB in 7MM (2017-2030)
  • Table 3 Prevalent Population of NCFB in the United States (2017-2030)
  • Table 4 Diagnosed Prevalent Population of NCFB in the United States (2017-2030)
  • Table 5 Gender Specific Diagnosed Prevalence of NCFB in the United States (2017-2030)
  • Table 6 Severity Specific Diagnosed prevalence NCFB in the United States (2017-2030)
  • Table 7 Etiology associated with NCFB in the United States (2017-2030)
  • Table 8 Microbiology of NCFB patients in the United States (2017-2030)
  • Table 9 Prevalent Population of NCFB in the Germany (2017-2030)
  • Table 10 Diagnosed Prevalent Population of NCFB in Germany (2017-2030)
  • Table 11 Gender Specific Diagnosed Prevalence of NCFB in Germany (2017-2030)
  • Table 12 Severity Specific Diagnosed prevalence NCFB in Germany (2017-2030)
  • Table 13 Etiology associated with NCFB in the Germany (2017-2030)
  • Table 14 Microbiology of NCFB patients in Germany (2017-2030)
  • Table 15 Prevalent Population of NCFB in France (2017-2030)
  • Table 16 Diagnosed Prevalent Population of NCFB in France (2017-2030)
  • Table 17 Gender Specific Diagnosed Prevalence of NCFB in France (2017-2030)
  • Table 18 Severity Specific Diagnosed prevalence NCFB in France (2017-2030)
  • Table 19 Etiology associated with NCFB in France (2017-2030)
  • Table 20 Microbiology of NCFB patients in France (2017-2030)
  • Table 21 Prevalent Population of NCFB in Italy (2017-2030)
  • Table 22 Diagnosed Prevalent Population of NCFB in Italy (2017-2030)
  • Table 23 Gender Specific Diagnosed Prevalence of NCFB in Italy (2017-2030)
  • Table 24 Severity Specific Diagnosed prevalence NCFB in Italy (2017-2030)
  • Table 25 Etiology associated with NCFB in Italy (2017-2030)
  • Table 26 Microbiology of NCFB patients in Italy (2017-2030)
  • Table 27 Prevalent Population of NCFB in the Spain (2017-2030)
  • Table 28 Diagnosed Prevalent Population of NCFB in Spain (2017-2030)
  • Table 29 Gender Specific Diagnosed Prevalence of NCFB in Spain (2017-2030)
  • Table 30 Severity Specific Diagnosed prevalence NCFB in Spain (2017-2030)
  • Table 31 Etiology associated with NCFB in Spain (2017-2030)
  • Table 32 Microbiology of NCFB patients in Spain (2017-2030)
  • Table 33 Prevalent Population of NCFB in the UK (2017-2030)
  • Table 34 Diagnosed Prevalent Population of NCFB in the UK (2017-2030)
  • Table 35 Gender Specific Diagnosed Prevalence of NCFB in the UK (2017-2030)
  • Table 36 Severity Specific Diagnosed prevalence NCFB in the UK (2017-2030)
  • Table 37 Etiology associated with NCFB in the UK (2017-2030)
  • Table 38 Microbiology of NCFB patients in the UK (2017-2030)
  • Table 39 Prevalent Population of NCFB in Japan (2017-2030)
  • Table 40 Diagnosed Prevalent Population of NCFB in Japan (2017-2030)
  • Table 41 Gender Specific Diagnosed Prevalence of NCFB in Japan (2017-2030)
  • Table 42 Severity Specific Diagnosed prevalence NCFB in Japan (2017-2030)
  • Table 43 Etiology associated with NCFB in Japan (2017-2030)
  • Table 44 Microbiology of NCFB patients in Japan (2017-2030)
  • Table 45 INS1007, Clinical Trial Description 2020
  • Table 46 Market size of NCFB in 7MM (2017-2030)
  • Table 47 The US Market of NCFB in USD Million (2017-2030)
  • Table 48 The US NCFB Market Size by Therapy in USD Million (2017-2030)
  • Table 49 The US Market of NCFB in Germany, USD Million (2017-2030)
  • Table 50 The NCFB Market Size by Therapy in Germany, USD Million (2017-2030)
  • Table 51 The Market of NCFB in France, USD Million (2017-2030)
  • Table 52 The NCFB Market Size by Therapy in France, USD Million (2017-2030)
  • Table 53 The Market of NCFB in Spain, USD Million (2017-2030)
  • Table 54 The NCFB Market Size by Therapy in Spain, USD Million (2017-2030)
  • Table 55 The Market of NCFB in Italy, USD Million (2017-2030)
  • Table 56 The NCFB Market Size by Therapy in Italy, USD Million (2017-2030)
  • Table 57 The Market of NCFB in UK, USD Million (2017-2030)
  • Table 58 The NCFB Market Size by Therapy in UK, USD Million (2017-2030)
  • Table 59 The Market of NCFB in Japan, USD Million (2017-2030)
  • Table 60 The NCFB Market Size by Therapy in Japan, USD Million (2017-2030)
  • Table 61 The Market of NCFB in Japan, USD Million (2017-2030)
  • Table 62 The NCFB Market Size by Therapy in Japan, USD Million (2017-2030)
  • Table 1 Conditions associated with the development of bronchiectasis
  • Table 2 Total Prevalent Population of NCFB in 7MM (2017-2030)
  • Table 3 Prevalent Population of NCFB in the United States (2017-2030)
  • Table 4 Diagnosed Prevalent Population of NCFB in the United States (2017-2030)
  • Table 5 Gender Specific Diagnosed Prevalence of NCFB in the United States (2017-2030)
  • Table 6 Severity Specific Diagnosed prevalence NCFB in the United States (2017-2030)
  • Table 7 Etiology associated with NCFB in the United States (2017-2030)
  • Table 8 Microbiology of NCFB patients in the United States (2017-2030)
  • Table 9 Prevalent Population of NCFB in the Germany (2017-2030)
  • Table 10 Diagnosed Prevalent Population of NCFB in Germany (2017-2030)
  • Table 11 Gender Specific Diagnosed Prevalence of NCFB in Germany (2017-2030)
  • Table 12 Severity Specific Diagnosed prevalence NCFB in Germany (2017-2030)
  • Table 13 Etiology associated with NCFB in the Germany (2017-2030)
  • Table 14 Microbiology of NCFB patients in Germany (2017-2030)
  • Table 15 Prevalent Population of NCFB in France (2017-2030)
  • Table 16 Diagnosed Prevalent Population of NCFB in France (2017-2030)
  • Table 17 Gender Specific Diagnosed Prevalence of NCFB in France (2017-2030)
  • Table 18 Severity Specific Diagnosed prevalence NCFB in France (2017-2030)
  • Table 19 Etiology associated with NCFB in France (2017-2030)
  • Table 20 Microbiology of NCFB patients in France (2017-2030)
  • Table 21 Prevalent Population of NCFB in Italy (2017-2030)
  • Table 22 Diagnosed Prevalent Population of NCFB in Italy (2017-2030)
  • Table 23 Gender Specific Diagnosed Prevalence of NCFB in Italy (2017-2030)
  • Table 24 Severity Specific Diagnosed prevalence NCFB in Italy (2017-2030)
  • Table 25 Etiology associated with NCFB in Italy (2017-2030)
  • Table 26 Microbiology of NCFB patients in Italy (2017-2030)
  • Table 27 Prevalent Population of NCFB in the Spain (2017-2030)
  • Table 28 Diagnosed Prevalent Population of NCFB in Spain (2017-2030)
  • Table 29 Gender Specific Diagnosed Prevalence of NCFB in Spain (2017-2030)
  • Table 30 Severity Specific Diagnosed prevalence NCFB in Spain (2017-2030)
  • Table 31 Etiology associated with NCFB in Spain (2017-2030)
  • Table 32 Microbiology of NCFB patients in Spain (2017-2030)
  • Table 33 Prevalent Population of NCFB in the UK (2017-2030)
  • Table 34 Diagnosed Prevalent Population of NCFB in the UK (2017-2030)
  • Table 35 Gender Specific Diagnosed Prevalence of NCFB in the UK (2017-2030)
  • Table 36 Severity Specific Diagnosed prevalence NCFB in the UK (2017-2030)
  • Table 37 Etiology associated with NCFB in the UK (2017-2030)
  • Table 38 Microbiology of NCFB patients in the UK (2017-2030)
  • Table 39 Prevalent Population of NCFB in Japan (2017-2030)
  • Table 40 Diagnosed Prevalent Population of NCFB in Japan (2017-2030)
  • Table 41 Gender Specific Diagnosed Prevalence of NCFB in Japan (2017-2030)
  • Table 42 Severity Specific Diagnosed prevalence NCFB in Japan (2017-2030)
  • Table 43 Etiology associated with NCFB in Japan (2017-2030)
  • Table 44 Microbiology of NCFB patients in Japan (2017-2030)
  • Table 45 INS1007, Clinical Trial Description 2020
  • Table 46 Market size of NCFB in 7MM (2017-2030)
  • Table 47 The US Market of NCFB in USD Million (2017-2030)
  • Table 48 The US NCFB Market Size by Therapy in USD Million (2017-2030)
  • Table 49 The US Market of NCFB in Germany, USD Million (2017-2030)
  • Table 50 The NCFB Market Size by Therapy in Germany, USD Million (2017-2030)
  • Table 51 The Market of NCFB in France, USD Million (2017-2030)
  • Table 52 The NCFB Market Size by Therapy in France, USD Million (2017-2030)
  • Table 53 The Market of NCFB in Spain, USD Million (2017-2030)
  • Table 54 The NCFB Market Size by Therapy in Spain, USD Million (2017-2030)
  • Table 55 The Market of NCFB in Italy, USD Million (2017-2030)
  • Table 56 The NCFB Market Size by Therapy in Italy, USD Million (2017-2030)
  • Table 57 The Market of NCFB in UK, USD Million (2017-2030)
  • Table 58 The NCFB Market Size by Therapy in UK, USD Million (2017-2030)
  • Table 59 The Market of NCFB in Japan, USD Million (2017-2030)
  • Table 60 The NCFB Market Size by Therapy in Japan, USD Million (2017-2030)
  • Table 61 The Market of NCFB in Japan, USD Million (2017-2030)
  • Table 62 The NCFB Market Size by Therapy in Japan, USD Million (2017-2030)

List of Figures

  • Figure 1 Common symptoms associated with non-CF bronchiectasis
  • Figure 2 Morphology of healthy and dilated bronchi
  • Figure 3 Representation of the cycle that leads to the development of bronchiectasis, as described by Cole
  • Figure 4 Airway obstruction, impaired mucociliary clearance, and other mechanisms promoting bronchiectasis
  • Figure 5 Algorithm for the diagnosis and etiologic investigation of bronchiectasis
  • Figure 6 Algorithm for the therapeutic management of stable bronchiectasis patients
  • Figure 7 Total Prevalent Population of NCFB in 7 MM (2017-2030)
  • Figure 8 Prevalent Population of NCFB in the United States (2017-2030)
  • Figure 9 Diagnosed Population of NCFB in the United States (2017-2030)
  • Figure 10 Gender Specific Diagnosed Prevalence of NCFB in the United States (2017-2030)
  • Figure 11 Severity Specific Diagnosed prevalence NCFB in the United States (2017-2030)
  • Figure 12 Etiology associated with NCFB in the United States (2017-2030)
  • Figure 13 Microbiology of NCFB patients in the United States (2017-2030)
  • Figure 14 Prevalent Population of NCFB in Germany (2017-2030)
  • Figure 15 Diagnosed Population of NCFB in Germany (2017-2030)
  • Figure 16 Gender Specific Diagnosed Prevalence of NCFB in Germany (2017-2030)
  • Figure 17 Severity Specific Diagnosed prevalence NCFB in Germany (2017-2030)
  • Figure 18 Etiology associated with NCFB in the Germany (2017-2030)
  • Figure 19 Microbiology of NCFB patients in Germany (2017-2030)
  • Figure 20 Prevalent Population of NCFB in France (2017-2030)
  • Figure 21 Diagnosed Population of NCFB in France (2017-2030)
  • Figure 22 Gender Specific Diagnosed Prevalence of NCFB in France (2017-2030)
  • Figure 23 Severity Specific Diagnosed prevalence NCFB in France (2017-2030)
  • Figure 24 Etiology associated with NCFB in France (2017-2030)
  • Figure 25 Microbiology of NCFB patients in France (2017-2030)
  • Figure 26 Prevalent Population of NCFB in Italy (2017-2030)
  • Figure 27 Diagnosed Population of NCFB in Italy (2017-2030)
  • Figure 28 Gender Specific Diagnosed Prevalence of NCFB in Italy (2017-2030)
  • Figure 29 Severity Specific Diagnosed prevalence NCFB in Italy (2017-2030)
  • Figure 30 Etiology associated with NCFB in Italy (2017-2030)
  • Figure 31 Microbiology of NCFB patients in Italy (2017-2030)
  • Figure 32 Prevalent Population of NCFB in Spain (2017-2030)
  • Figure 33 Diagnosed Population of NCFB in Spain (2017-2030)
  • Figure 34 Gender Specific Diagnosed Prevalence of NCFB in Spain (2017-2030)
  • Figure 35 Severity Specific Diagnosed prevalence NCFB in Spain (2017-2030)
  • Figure 36 Etiology associated with NCFB in Spain (2017-2030)
  • Figure 37 Microbiology of NCFB patients in Spain (2017-2030)
  • Figure 38 Prevalent Population of NCFB in the UK (2017-2030)
  • Figure 39 Diagnosed Population of NCFB in the UK (2017-2030)
  • Figure 40 Gender Specific Diagnosed Prevalence of NCFB in the UK (2017-2030)
  • Figure 41 Severity Specific Diagnosed prevalence NCFB in the UK (2017-2030)
  • Figure 42 Etiology associated with NCFB in the UK (2017-2030)
  • Figure 43 Microbiology of NCFB patients in the UK (2017-2030)
  • Figure 44 Prevalent Population of NCFB in Japan (2017-2030)
  • Figure 45 Diagnosed Population of NCFB in Japan (2017-2030)
  • Figure 46 Gender Specific Diagnosed Prevalence of NCFB in Japan (2017-2030)
  • Figure 47 Severity Specific Diagnosed prevalence NCFB in Japan (2017-2030)
  • Figure 48 Etiology associated with NCFB in Japan (2017-2030)
  • Figure 49 Microbiology of NCFB patients in Japan (2017-2030)
  • Figure 50 Unmet needs for NCFB
  • Figure 51 Market Size of NCFB in 7 MM (2017-2030)
  • Figure 52 Market Size of NCFB in the United States, USD Millions (2017-2030)
  • Figure 53 The U.S. NCFB Market Size by Therapy USD Million (2017-2030)
  • Figure 54 Market Size of NCFB in Germany, USD Millions (2017-2030)
  • Figure 55 The NCFB Market Size by Therapy in Germany, USD Million (2017-2030)
  • Figure 56 Market Size of NCFB in France, USD Millions (2017-2030)
  • Figure 57 The NCFB Market Size by Therapy in France, USD Million (2017-2030)
  • Figure 58 Market Size of NCFB in Spain, USD Millions (2017-2030)
  • Figure 59 The NCFB Market Size by Therapy in Spain, USD Million (2017-2030)
  • Figure 60 Market Size of NCFB in Italy, USD Millions (2017-2030)
  • Figure 61 The NCFB Market Size by Therapy in Italy, USD Million (2017-2030)
  • Figure 62 Market Size of NCFB in the UK, USD Millions (2017-2030)
  • Figure 63 The U.S. NCFB Market Size by Therapy in the UK, USD Million (2017-2030)
  • Figure 64 Market Size of NCFB in Japan, USD Millions (2017-2030)
  • Figure 65 The NCFB Market Size by Therapy in Japan, USD Million (2017-2030)
  • Figure 66 Market drivers for NCFB
  • Figure 67 Market Barriers for NCFB